Treating schizophrenia: Should we emphasise 'first do no harm'?
Tom English, David Castle
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY | SAGE PUBLICATIONS LTD | Published : 2021
The author(s) declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: D.C. has received grant monies for research from Eli Lilly, Janssen Cilag, Roche, Allergen,Bristol-Myers Squibb, Pfizer, Lundbeck, Astra Zeneca and Hospira; Travel Support and Honoraria for Talks and Consultancy from Eli Lilly, Bristol-Myers Squibb, Astra Zeneca, Lundbeck, Janssen Cilag, Pfizer, Organon, Sanofi-Aventis, Wyeth, Hospira, Servier and Seqirus; and is a current or past Advisory Board Member for Lu AA21004: Lundbeck; Varenicline: Pfizer; Asenapine: Lundbeck; Aripiprazole LAI: Lundbeck; Lisdexamfetamine: Shire; Lurasidone: Servier; Brexpiprazole: Lundbeck; Treatment Resistant Depression: LivaNova; and Cariprazine: Seqirus. He is founder of the Optimal Health Program, currently operating as Optimal Wellness; and is part owner of Clarity Healthcare. He is on the scientific advisory of The Mental Health Foundation of Australia. He does not knowingly have stocks or shares in any pharmaceutical company. He was a member of the original schizophrenia and related disorders CGP working group: the views expressed here have been endorsed by neither that group nor the RANZCP.